ABOUT BIOMARIN
Founded 25 years ago, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery.
Learn More about BioMarin ⌃CAREERS AT BIOMARIN
Our focus on genetic disease gives us the opportunity to truly impact lives.
Learn More about careers with BioMarin ⌃
Patient & Community Support
Treatment is only the beginning.
We are committed to the communities we treat beyond the therapies
OUR PIPELINE
We maximize the impact of genetic innovation to develop transformative therapies.
We recently presented an update on our pipeline at our 2023 R&D Day. View the replay on our Investor
-
November 28, 2023BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Germany
-
November 1, 2023BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year
-
November 1, 2023BioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive Officer
-
October 20, 2023U.S. Food and Drug Administration Approves BioMarin’s VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia
-
October 17, 2023BioMarin to Host Third-Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, November 1, at 4:30pm ET
-
September 21, 2023BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting
-
September 15, 2023BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia
-
September 11, 2023BioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York